EWA
ARQT icon

EverSource Wealth Advisors’s Arcutis Biotherapeutics ARQT Stock Holding History

EverSource Wealth Advisors’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$15.9K Sell
608
-53
-8% -$1.24K ﹤0.01% 2606
2026
Q1 		$15.6K Sell
661
-600
-48% -$15.3K ﹤0.01% 2657
2025
Q4 		$36.6K Buy
1,261
+698
+124% +$17.9K ﹤0.01% 1967
2025
Q3 		$10.6K Buy
563
+80
+17% +$1.26K ﹤0.01% 2795
2025
Q2 		$6.77K Buy
483
+246
+104% +$3.45K ﹤0.01% 3030
2025
Q1 		$3.71K Buy
237
+153
+182% +$2.15K ﹤0.01% 2642
2024
Q4 		$1.17K Buy
+84
New +$920 ﹤0.01% 2912

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

EverSource Wealth Advisors's ARQT Position: Q2 2026 in Review

EverSource Wealth Advisors reduced its Arcutis Biotherapeutics (ARQT) stake by 8% in Q2 2026, selling an estimated $1.24K and leaving 608 shares worth $15.9K. The position accounts for ﹤0.01% of the portfolio, ranked #2606.

EverSource Wealth Advisors first reported a position in ARQT in Q4 2024 and has held it in 7 quarters since. The position peaked at $36.6K in Q4 2025. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • EverSource Wealth Advisors held 608 shares of Arcutis Biotherapeutics worth $15.9K as of Q2 2026.
  • EverSource Wealth Advisors sold 53 Arcutis Biotherapeutics shares in Q2 2026, an estimated $1.24K.
  • Arcutis Biotherapeutics made up ﹤0.01% of EverSource Wealth Advisors's portfolio in Q2 2026, its #2606 holding.
  • EverSource Wealth Advisors first reported a position in Arcutis Biotherapeutics in Q4 2024 and has held it in 7 quarters since.
  • EverSource Wealth Advisors's Arcutis Biotherapeutics position peaked at $36.6K in Q4 2025.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on EverSource Wealth Advisors's 13F filing for Q2 2026, filed 24 Jul 2026.